Unknown Primary Clinical Trials in Georgia

Cancer Type = Unknown Primary

Cancer Type = Unknown Primary

There are currently 134 active Unknown Primary clinical trials in Georgia.
4.
A Phase 1 / 2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR / HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT02716116
Protocol IDs
AP32788-15-101
NCI-2016-00587
U1111-1217-7205
7.
A Phase 1 / 2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Cancer Type
Unknown Primary
NCI ID
NCT02929862
Protocol IDs
LYC-55716-1001
NCI-2016-01930
LYC-55716
11.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
12.
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
15.
A Phase 1 Study of ASP1951 in Subjects With Advanced Solid Tumors
Cancer Type
Lung Cancer, Prostate Cancer , Unknown Primary
NCI ID
NCT03799003
Protocol IDs
1951-CL-0101
NCI-2019-02414
16.
A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT03030378
Protocol IDs
10061
10061
NCI-2017-00091
HCC 17-003
17.
A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Skin Cancer (Non-Melanoma), Thyroid Cancer, Unknown Primary
NCI ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
18.
A Phase 1 Study of Palbociclib in Combination with Cisplatin or Carboplatin in Advanced Solid Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02897375
Protocol IDs
Winship3263-16
NCI-2016-01037
IRB00089583
21.
A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Cancer Type
Brain Cancer , Eye Cancer, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT02323880
Protocol IDs
ADVL1414
NCI-2014-02410
22.
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTS
Cancer Type
Lymphoma, Unknown Primary
NCI ID
NCT03726333
Protocol IDs
B7461009
NCI-2019-01060
HEPATIC IMPAIRMENT
lorlatinib HEPATIC IMPAIRMENT
23.
A Phase 1 Study Using Simvastatin in Combination With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02390843
Protocol IDs
IRB00078790
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03415126
Protocol IDs
ASN007-101
NCI-2018-00820
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.